A board-level investor at ILMN filed a flurry of sales this week. Keith Meister, whose asset management firm holds a board seat, sold over $148 million worth of Illumina shares across 14 transactions filed on August 6. The trades occurred on August 4 and 5, at prices between $198 and $203 per share.
At the other end of the spectrum, buyers stepped up at BSX. CEO Michael Mahoney bought $9 million worth of Boston Scientific stock on August 3. That filing hit on August 5. CEO purchases at this scale are rare and often read as a strong vote of confidence in the company's outlook.
Two PFE directors filed purchases on August 5. Ronald Blaylock and Tim Buckley each bought roughly $1 million in Pfizer shares. The stock trades near multi-year lows around $25. Two directors buying on the same day stands out as a clear signal.
LUMN CEO Kate Johnson also put $613,000 of her own money into Lumen Technologies stock on August 6. That filing landed the same day. It marks a meaningful personal bet by the chief executive of a telecom turnaround story.
Meanwhile, JNJ Chairman and CEO Joaquin Duato sold $10.8 million worth of Johnson & Johnson shares on August 5. director John Hess sold $10.8 million in Chevron stock around the same time.
The pattern is clear: insiders at beaten-down stocks are buying, while those sitting on gains are locking in profits.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
